Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,606.49
(
-0.27%
)
US TECH 100
23,763.96
(
-0.13%
)
Dow Jones
46,021.43
(
-0.44%
)
Brent Oil
103.84
(
-0.57%
)
Bitcoin
70,635.00
(
1.05%
)
News Focus
News Focus
Post# of 257262
Next 10
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122802
Boards Moderated 10
Alias Born 09/05/2002

DewDiligence

Member Level

Re: DewDiligence post# 197120

Friday, 03/31/2017 10:53:32 AM

Friday, March 31, 2017 10:53:32 AM

Post# of 257262
CHMP approves Samsung-Bioepis/BIIB’s Enbrel FoB:

http://www.businesswire.com/news/home/20151120005300/en/Samsung-Bioepis-Receives-Positive-CHMP-Opinion-Etanercept

The is the first Enbrel FoB in the EU. BIIB has the marketing rights to this product in the EU, Japan, and Switzerland.

This product will not be commercialized in the US due to AMGN's long-running US Enbrel patent.

Note: The EU does not have a provision for approving interchangeable FoBs.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Trade Smarter with Thousands

Leverage decades of market experience shared openly.

Join Now